Drug Approval | December 20, 2023
Briefs: Aurobindo Pharma and Granules Pharmaceuticals
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Pantoprazole Sodium Delayed-Release Tablets are indicated for short-term treatment of Erosive Esophagitis associated with GERD
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Express Scripts to add Zepbound to National Preferred Formulary
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of US $33 million in the US
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Subscribe To Our Newsletter & Stay Updated
